Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
One Percent Rule Checklist For Safer Forex Trading Risk 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TEL AVIV, Israel, April 06, 2017 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its previously announced underwritten public offering of the Company’s securities due to adverse market conditions. H.C. Wainwright had been serving as the underwriters for the proposed offering. The offering was conducted pursuant to a registration statement Form F-1 filed with the U.S. Securities and Exchange Commission.
The Company will provide a business update in the near future that deals with its financing plans and clinical development program for patients with Ocular Pharyngeal Muscular Dystrophy (OPMD) using its investigational proprietary intravenous (IV) form of trehalose 90 mg/mL solution.
About Bioblast Pharma Ltd.
Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Bioblast is traded on the NASDAQ under the symbol “ORPN.” For more information, please visit our website: www.BioblastPharma.com, the content of which is not incorporated herein by reference.
INVESTOR CONTACT Matthew P. Duffy Managing Director LifeSci Advisors LLC [email protected] Phone: 212-915-0685
